Log In Sign up
The largest database of trusted experimental protocols
> Devices > Medical Device > Bioreactors

Bioreactors

Bioreactors are essential tools for the cultivation and production of various biological materials, including cells, tissues, and microbial cultures.
These specialized vessels provide a controlled environment for the growth and optimization of biological processes.
Bioreactors enable researchers and industry professionals to manipulate parameters such as temperature, pH, oxygen levels, and nutrient supply to enhance the yield, productivity, and quality of their desired products.
From pharmaceutical development to environmental biotechnology, bioreactors play a crucial role in a wide range of applications, contributing to advancements in fields like medicine, agriculture, and sustainable energy.
Reasearch into bioreactor design, monitoring, and optimization continues to drive innovation and expand the capabilities of this versatile technology.

Most cited protocols related to «Bioreactors»

1
Cerebral Organoid Generation from Human Pluripotent Stem Cells
Human H9 ES (WA09) were obtained from WiCell at passage 26 with verified normal karyotype and contamination-free. iPS cells were obtained from System Biosciences (SC101A-1) verified pluripotent and contamination free. All human PSC lines were regularly checked and confirmed negative for mycoplasma. PSCs were maintained on CF-1 gamma irradiated MEFs (Global Stem) according to WiCell protocols. On day 0 of organoid culture, ESCs or iPSCs less than passage 50 were dissociated from MEFs by dispase treatment and MEFs were removed by gravity separation of stem cell colonies from MEFs before trypsinization of stem cells to generate single cells. 4500 cells were then plated in each well of an ultra-low binding 96-well plate (Corning) in hES media with low bFGF (5-fold reduced) and 50uM ROCK inhibitor49 (link) (Calbiochem).
EBs were fed every other day for 6 days then transferred to low adhesion 24-well plates (Corning) in neural induction media containing DMEM/F12, 1:100 N2 supplement (Invitrogen), Glutamax (Invitrogen), MEM-NEAA, and 1ug/ml Heparin50 (link) (Sigma). These began forming neuroepithelial tissues, which were fed every other day for 5 days. On Day 11 of the protocol, tissues were transferred to droplets of Matrigel (BD Biosciences) by pipetting into cold Matrigel on a sheet of Parafilm with small 3mm dimples. These droplets were allowed to gel at 37C and were subsequently removed from the Parafilm and grown in differentiation media containing a 1:1 mixture of DMEM/F12 and Neurobasal containing 1:200 N2 supplement (Invitrogen), 1:100 B27 supplement without vitamin A (Invitrogen), 3.5ul/L 2-mercaptoethanol, 1:4000 insulin (Sigma), 1:100 Glutamax (Invitrogen), 1:200 MEM-NEAA.
After 4 days of stationary growth, the tissue droplets were transferred to a spinning bioreactor containing differentiation media as above except B27 supplement with vitamin A (Invitrogen) was used. Since retinoic acid has been shown to be important for neuronal differentiation in vivo52 (link), we included it in the final media used to differentiate the cerebral organoids.
Lancaster M.A., Renner M., Martin C.A., Wenzel D., Bicknell L.S., Hurles M.E., Homfray T., Penninger J.M., Jackson A.P, & Knoblich J.A. (2013). Cerebral organoids model human brain development and microcephaly. Nature, 501(7467), 10.1038/nature12517.
Publication 2013
2-Mercaptoethanol Bioreactors Cells Cell Separation Common Cold Dietary Supplements dispase Enhanced S-Cone Syndrome Gamma Rays Gravity Homo sapiens Induced Pluripotent Stem Cells Insulin Karyotyping matrigel Mycoplasma Nervousness Neurons Organoids Pancreatic Stellate Cells Stem, Plant Stem Cells Tissues Tretinoin Vitamin A
2
Differentiation of Mouse A9 Organoids
Mouse A9 ES cells were cultured on Mitomycin C growth inactivated MEFs and passaged according to standard protocols53 . For the generation of mouse organoids, the organoid protocol was applied with the following modifications: cells were trypsinized and 2000 stem cells were plated in each well of an ultra-low binding 96-well plate in differentiation medium as described by Eiraku et al.20 (link) (Medium containing 10uM SB431542 but without Dkk-1). Subsequent steps were followed according to the human organoid method using identical media compositions, with the exception that for mouse tissues faster timing was used according to morphology. EBs were transferred to neural induction medium on day 4, embedded in matrigel droplets on day 6, and on day 9 transferred to the spinning bioreactor.
Lancaster M.A., Renner M., Martin C.A., Wenzel D., Bicknell L.S., Hurles M.E., Homfray T., Penninger J.M., Jackson A.P, & Knoblich J.A. (2013). Cerebral organoids model human brain development and microcephaly. Nature, 501(7467), 10.1038/nature12517.
Publication 2013
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide Bioreactors Cells Embryonic Stem Cells Homo sapiens matrigel Mitomycin Mus Organoids Stem Cells Tissues
3
Single-cell transcriptomics of human brain organoids
For the 6 mo dataset, we sequenced 19 organoids from 4 bioreactors: 4 organoids from bioreactor 1 (Org1A, 3,547 cells; Org1B, 3,463 cells; Org1C, 3,698 cells; Org1D, 2,811 cells), 3 organoids from bioreactor 2 (Org2A, 2,238 cells; Org2B, 3,159 cells; Org2C, 2,708 cells), 4 organoids from bioreactor 3 (Org3A, 4,225 cells; Org3B, 2,557 cells; Org3C, 3,614 cells; Org3D, 11,061 cells) and 8 organoids from bioreactor 4 (Org4A, 1,656 cells; Org4B, 1,663 cells; Org4C, 1,795 cells; Org4D, 2,151 cells; Org4E, 3,407 cells; Org4F 7,443 cells; Org4G, 2,905 cells; Org4H, 2,788 cells). For the 3 mo dataset, we sequenced 12 organoids from bioreactor 6 (8,478 cells) and bioreactor 7 (6,924 cells).
Droplets containing single cells and barcoded micro-particles were generated and processed as described in 11 (link). Briefly, droplets were collected and beads were recovered and processed for immediate reverse transcription. The resulting cDNA was amplified, fragmented and further amplified using the Nextera XT DNA library preparation kit. Sequencing was performed on the Illumina NextSeq 500.
Clustering of cells derived from 6-month organoids was performed using the Seurat R package12 (link), with some modifications from the procedure described previously11 (link). Clustering was done in two iterative rounds of principal components analysis (PCA). First, digital gene expression matrices were column-normalized and log-transformed. Cells with fewer than 400 expressed genes were removed from analysis. A set of variable genes was then identified by binning the average expression of all genes into 300 evenly sized groups and computing the median dispersion (variance divided by the mean) in each bin. Genes were selected for inclusion in PCA that had higher than twice the median dispersion, minus the minimum value (final set: 1,568 genes). The edges of a nearest neighbor graph were generated by computing the fraction of shared nearest neighbors amongst cells in the first 20 PC dimensions using the approximate nearest neighbors package (ANN) in R (CRAN), setting the k parameter to 25 (“BuildSNN” function in Seurat). A first round of clustering with the Louvain modularity-based community detection algorithm39 (link) set at a resolution of 0.01 was used to generate a total of 10 first-round clusters (“FindClusters” function in Seurat). The largest 50% of the cells from each of these clusters was again subjected to gene selection and PCA. These PCs were evaluated for statistically significant gene expression signals using the Jackstraw method11 (link),40 (link) (“JackStraw” function in Seurat). At most 15 PCs were used in this second round of clustering by Louvain, with the resolution parameter set at 3. The resulting clusters were compared pairwise for differential expression, as in11 (link), and clusters with fewer than 10 genes differentially expressed by more than 2-fold were merged, producing 202 clusters. For analysis of organoid-to-organoid variability, organoids were excluded from a given cluster if they contributed less than 1% of the cells in that cluster.
Correlation analysis between gene expression in a dataset of human fetal cortex22 (link) against the astrocyte cluster (c2) and the identified subclusters of the forebrain cluster (c4) was performed using the log average expression of a set of 104 genes, identified by taking the top 10 most differentially expressed genes for each cluster pair in the published fetal cortex dataset (some of which overlapped) as the most informative for distinguishing the reported endogenous cell classes of the cortex. We then constructed expression profiles for the six organoid cell groups and measured the correlation of gene expression levels for the 104 endogenous genes, comparing each of the endogenous cortical cell classes to each of the organoid cell groups. For the retinal subclusters (subclusters of c5), we repeated this correlation analysis against a dataset of P14 mouse retina11 (link), using 110 genes, identified by taking the top 10 most enriched genes from the 11 major cell classes (horizontal cells, retinal ganglion cells, amacrine cells, photoreceptors, bipolar cells, and six glial retinal types) in the mouse dataset, and correlating against the expression profiles of the orthologous human genes in the six organoid retinal cell groups.
Quadrato G., Nguyen T., Macosko E.Z., Sherwood J.L., Yang S.M., Berger D., Maria N., Scholvin J., Goldman M., Kinney J., Boyden E.S., Lichtman J., Williams Z.M., McCarroll S.A, & Arlotta P. (2017). Cell diversity and network dynamics in photosensitive human brain organoids. Nature, 545(7652), 48-53.
Publication 2017
Adrenal Cortex Amacrine Cells Astrocytes Bioreactors Cells Cortex, Cerebral DNA, Complementary DNA Library Fetus Fingers Gene Expression Gene Expression Profiling Genes Genes, vif Genetic Selection Germ Cells Homo sapiens Mus Neuroglia Organoids Photoreceptor Cells Prosencephalon Retina Retinal Ganglion Cells
4
SARS-CoV-2 Virus Titer Determination

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2020
Biological Assay Bioreactors Buffers Cells Chinese Chromatography Dietary Fiber Hydroxide, Aluminum Microscopy Patients Pharmaceutical Adjuvants Phosphates Propiolactone SARS-CoV-2 Technique, Dilution Vaccination Vaccines Vero Cells Virus
5
Enzymatic Hydrolysis of AFEX-Pretreated Corn Stover
AFEX-CS was enzymatically hydrolyzed with a commercial enzyme mixture as previously described [10 (link)]. The enzyme mixture was composed of Spezyme™ CP (79.6 mL/kg CS; protein concentration: 88 mg/mL), Novozyme™ 188 (40.1 mL/kg CS; protein concentration: 150 mg/mL), Multifect Xylanase (11.6 mL/kg CS; protein concentration: 35 mg/mL), and Multifect Pectinase (8.2 mL/kg CS; protein concentration: 90 mg/mL). Spezyme™ CP and Multifect enzyme cocktails were obtained from Genencor Inc., while Novozyme™ 188 was procured from Sigma-Aldrich Co. The glucan loading used for biomass hydrolysis was 6% by weight, which was equivalent to about 19% solids loading. The enzymatic hydrolysis was performed in a 3-L glass autoclavable bioreactor equipped with ez-Control (Applikon Biotechnology B.V., Schiedam, Netherlands) at 50°C and 1,000 rpm for 96 h. A total of 2.5 kg of reaction contents (biomass, water, enzymes, and antibiotics) was loaded into the reactor with biomass added in two batches separated by 3 h intervals. The pH was maintained at 4.8 with 6 M KOH during the course of hydrolysis. Chloramphenicol (Sigma-Aldrich, St. Louis, MO, USA) was added at a final concentration of 50 mg/L to minimize the risk of microbial contamination. The hydrolyzed mixture was separated by centrifugation at 8,000 rpm for 30 min, and the separated supernatant was heat-deactivated by heating the hydrolysate for 15 min at 90°C in a water bath and filtered with a 0.22-μm sterile filter (Millipore Stericup®, Millipore™, Billerica, MA, USA). The filtrate was collected and stored in the freezer until further use.
Tang X., da Costa Sousa L., Jin M., Chundawat S.P., Chambliss C.K., Lau M.W., Xiao Z., Dale B.E, & Balan V. (2015). Designer synthetic media for studying microbial-catalyzed biofuel production. Biotechnology for Biofuels, 8, 1.
Publication 2015
Antibiotics, Antitubercular Bath Bioreactors Centrifugation Chloramphenicol Enzymes Glucans Hydrolysis Novozym 188 Polygalacturonase Proteins Sterility, Reproductive

Most recents protocols related to «Bioreactors»

1
Yeast-based Galactose Degradation in Foods
Not available on PMC !

Example 4

As part of evaluating the feasibility of a yeast-based approach as a treatment to mitigate the effects of elevated concentrations of galactose in foods and beverages, several evolved clones were tested for their capability of degrading galactose when present in food. Milk was tested because it represents the most challenging food for galactosemia patients considering its high level of galactose (2-4 g per 100 mL of milk). Food spiked with galactose was tested in parallel.

For this study, three evolved yeast strains obtained by adaptive evolution followed by UV treatment, Clone Y-C201-1, Clone Y-C202-1, and Clone Y-C202-2, one evolved yeast strain obtained by adaptive evolution, Clone Y-C202, as well as the initial parent strain Yi were compared for their galactose consumption activity. Cultures were initiated from a single colony on agar plates and grown in 15 mL of liquid YP medium (1% yeast extract, 2% peptone; Teknova, Hollister, CA) in a 50-mL mini-bioreactor by incubation at 30° C. with an agitation of 225 rpm supplemented with 2% galactose (Teknova). Strain Saccharomyces boulardii (SB) was prepared similarly to the evolved clones except that it was grown in YP medium supplemented with 2% glucose.

The testing of galactose consumption was started with yeast cells obtained from a culture volume containing 1.0×109 Colony Forming Units (CFU) pelleted by centrifugation at 1000 rpm (Sorval, RT7) for 10 min at room temperature. Cell pellets were resuspended either in 1.0 mL of milk already pre-treated with lactase (LACTAID milk where lactose is transformed into galactose and glucose) or in 1 mL rodent diet (Teklad, Envigo) spiked with a solution of 5% galactose or a solution of 5% galactose+1% glucose. All the reactions were incubated at 37° C. Aliquots of the reactions were taken at multiple time points and stored at −20° C. until galactose concentration determination.

[Figure (not displayed)]

US11865151B2. Live biotherapeutics for the treatment of carbohydrate disorders (2024-01-09). GUTSYBIO INC. [US]. Inventors: Genevieve Hansen [US].
Patent 2024
Acclimatization Agar Beverages Biological Evolution Bioreactors Cells Centrifugation Clone Cells Diet Food Galactose Galactosemias Glucose Lactaid Lactase Lactose Milk, Cow's Parent Patients Pellets, Drug Peptones Rodent Saccharomyces boulardii Strains Yeast, Dried
2
Yeast-Based Fructose Degradation Potential
Not available on PMC !

Example 10

As part of evaluating the feasibility of a yeast-based approach as a treatment to mitigate the effects of elevated concentrations of fructose in foods and beverages, several evolved clones obtained by adaptive evolution were tested for their ability of degrading fructose when present in food.

For this study, two evolved yeast strains obtained by adaptive evolution, G1_1A and G2_1A were tested for their ability to degrade dietary fructose. The testing of fructose consumption was started with yeast cells obtained from a culture initiated from a single colony on agar plates and grown in 15 mL of liquid YP medium in a 50-mL mini-bioreactor by incubation at 30° C. with an agitation of 225 rpm supplemented with 4% fructose. Cells were pelleted by centrifugation at 1000 rpm (Sorval, RT7) for 10 min at room temperature. Cell pellets were resuspended in 5 mL rodent diet (Teklad, Envigo) spiked with a solution of 10% fructose (=555 mM). Reactions were incubated at 37° C. to mimic human gastrointestinal temperature conditions. Aliquots of the reactions were taken at multiple time points and stored at −20° C. until fructose concentration determination using the colorimetric Fructose Assay Kit (Cat. No. EFRU-100; BioAssay Systems, Hayward, CA).

As shown in Table 12, the evolved clones were able to rapidly decrease fructose concentration when present in diet.

TABLE 12
Remaining Fructose (%) after Exposure for 0.5 to 3 Hours to a Solution
of 10% Fructose with Evolved Clones G1_1A and G2_1A
CloneG1_1AG1_1AG1_1AG2_1AG2_1AG2_1A
CFU/mL3.10E+096.21E+092.17E+103.39E+096.78E+092.37E+10
Time point: 0.5 hr111.1%88.2%45.9%91.3%76.8%37.8%
Time point: 2.0 hr78.0%53.2%6.3%77.2%53.3%5.6%
Time point: 3.0 hr60.8%35.2%−1.5%59.7%34.7%−0.5%

US11865151B2. Live biotherapeutics for the treatment of carbohydrate disorders (2024-01-09). GUTSYBIO INC. [US]. Inventors: Genevieve Hansen [US].
Patent 2024
Acclimatization Agar Beverages Biological Assay Biological Evolution Bioreactors Cells Centrifugation Clone Cells Colorimetry Diet Food Fructose Gastrointestinal Diseases Homo sapiens Pellets, Drug Rodent Strains Yeast, Dried
3
Engineered Strain Degrades Methionine
Not available on PMC !

Example 8

SYNB1353 comprises a metP gene, metDC gene, and deletion of the yjeH gene, as shown in FIG. 14A. The ability of SYNB1353 to degrade methionine to 3-MTP and CO2 by its engineered pathway was measured.

SYNB1353 and SYN094 were grown and activated in a bioreactor following optimized processes intended to be used for the scale-up of drug product. Activated cell batches were resuspended to the specified live cell count in assay media, and cells were statically incubated at 37° C. Supernatants were collected at defined timepoints, and the quantity of each analyte (methionine and 3-MTP) in each sample was determined by liquid chromatography mass spectrometry (LC-MS/MS). As observed in FIG. 14B, SYNB1353 degraded methionine and produced 3-MTP de novo, as designed. The control strain, SYN094, consumed methionine at a low rate and did not produce any 3-MTP.

In vitro Met consumption assays, as described above, show consumption of methionine and production of 3-MTP by SYNB1353 and not the EcN control (FIG. 14B). In vitro, SYNB1353 consumed methionine at a rate of 1.3±0.13 μmol/h/1×109 live cells and concomitantly produced 3-MTP at a rate of 1.3±0.087 μmol/h/1×109 live cells.

US11859189B2. Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof (2024-01-02). Synlogic Operating Company, Inc. [US], Ginkgo Bioworks, Inc. [US]. Inventors: Dylan Alexander Carlin [US], Vincent M. Isabella [US], Jonathan McMurry [US], Theodore Carlton Moore, III [US], Mylene Perreault [US], Nathan Schmidt [US], Mark Simon [US].
Patent 2024
Biological Assay Bioreactors Cells Gene Deletion Genes Liquid Chromatography Mass Spectrometry Methionine Pharmaceutical Preparations Strains
4
Assessing LAAD Expression Effect on Phe Metabolism
Not available on PMC !

Example 74

Efficacy of of LAAD expression and determination of any negative effects on PAL metabolism of Phe was assessed.

At T=0, the urine pan was emptied, and Non-Human Primates (NHPs) were orally administered 5.5 g of Peptone from meat in 11 mL, and 10 mL of an oral gavage bacteria. A SYN-PKU-2001 (5×1011 CFU) oral gavage bacteria strain was administered to NHP's 1-3. A SYN-PKU-2001 (5×1011 CFU) without LAAD was administered to NHP's 4-6. Both strains were suspended in formulation buffer (previously grown in activated in a bioreactor and thawed on ice) or formulation buffer alone as a mock. Concurrently, NHP's 1-10 were all administered 5 mL of 0.36M sodium bicarbonate followed by a flush with 5 mL of water Animals were bled at 0, 0.5, 1, 2, 4, and 6 h by venipuncture. At 6 h post dosing, the urine collection pan was removed and the contents poured into a graduated cylinder for volume measurement of 5 mL. Results are shown in FIG. 24A and FIG. 24B confirm that expression of LAAD did not have a negative effect on PAL metabolism of Phe.

US11879123B2. Bacteria for the treatment of disorders (2024-01-23). Synlogic Operating Company, Inc. [US]. Inventors: Dean Falb [US], Adam B. Fisher [US], Vincent M. Isabella [US], Jonathan W. Kotula [US], David Lubkowicz [US], Paul F. Miller [US], Yves Millet [US], Sarah Elizabeth Rowe [US].
Patent 2024
Animals Bacteria Bicarbonate, Sodium Bioreactors Buffers Flushing Homo sapiens Meat Metabolism Peptones Primates Strains Tube Feeding Urine Urine Specimen Collection Venipuncture
5
Mycelium Cultivation via Liquid Fermentation
Not available on PMC !

Example 1

The mycelium is cultivated via a liquid state fermentation to mycelium extractable culture. Firstly, a pure culture of mycelium grown on agar tube MEA (Malt Extract Agar) medium or liquid culture syringe is used to inoculate the 1st mycelium generation G1 on agar plate. Once the agar plate is fully colonised (10-14 days), this 1st generation is used to inoculate a 20 litre mycelium bioreactor with nutrient solutions to create the 2nd mycelium generation G2. Finally, after the bioreactor is fully colonised by the mycelium (14 days), it is used to inoculate a 1000 litre mycelium bioreactor which constitutes the 3rd mycelium generation G3. Liquid inoculation is preferred for liquid fermentation in the bioreactor, although inoculation with colonized agar may be utilized, and inoculation with colonized grain is preferred for sawdust or wood chip substrates. When the mycelium reaches a dense mass of growth (preferably after 20 but before 120 days growth in fermentation or in solid state fermentation subsequent to inoculation, but well before fruit body formation) mycelial mass can be extracted with additional alcohol.

US11857587B2. Bioactive extract (2024-01-02). Mycelium Biotech Assets Pty Ltd [AU]. Inventors: Thomas Loussier [FR], Julian Mitchell [AU].
Patent 2024
Agar Bioreactors Cereals DNA Chips Ethanol Fermentation Fruit Human Body Mycelium Nutrients Syringes Triticum aestivum Vaccination

Top products related to «Bioreactors»

1
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
2
Penicillin streptomycin by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia
Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.
3
Biostat b plus by Sartorius
Sourced in Germany
The Biostat B Plus is a compact and versatile bioreactor system designed for cell culture, microbial, and biochemical applications. It offers precise control and monitoring of key process parameters, including temperature, pH, and dissolved oxygen. The system is suitable for working volumes ranging from 2 to 30 liters and can be configured with a variety of sensors and accessories to meet specific research or production requirements.
4
Antifoam 204 by Merck Group
Sourced in United States, Germany
Antifoam 204 is a silicone-based defoaming agent. It is designed to suppress foaming in various industrial processes.
5
Biostat a plus by Sartorius
Sourced in Germany
The Biostat A Plus is a compact, all-in-one bioreactor system designed for cell culture and microbial fermentation applications. It features a stainless steel vessel with a working volume range of 0.5 to 10 liters. The system provides automated control of critical parameters such as temperature, pH, dissolved oxygen, and agitation speed.
6
Bioflo 110 by Eppendorf
Sourced in United States, Germany
The BioFlo 110 is a compact, versatile benchtop bioreactor system designed for small-scale cell culture and fermentation applications. It provides precise control and monitoring of key process parameters, including temperature, pH, dissolved oxygen, and agitation speed. The BioFlo 110 is suitable for a variety of cell types and microbial cultures, enabling researchers to conduct experiments and optimize processes in a controlled laboratory environment.
7
L glutamine by Thermo Fisher Scientific
Sourced in United States, United Kingdom, Germany, France, Canada, Switzerland, Italy, Australia, Belgium, China, Japan, Austria, Spain, Brazil, Israel, Sweden, Ireland, Netherlands, Gabon, Macao, New Zealand, Holy See (Vatican City State), Portugal, Poland, Argentina, Colombia, India, Denmark, Singapore, Panama, Finland, Cameroon
L-glutamine is an amino acid that is commonly used as a dietary supplement and in cell culture media. It serves as a source of nitrogen and supports cellular growth and metabolism.
8
Biostat b by Sartorius
Sourced in Germany
The Biostat B is a compact and versatile bioreactor system from Sartorius. It is designed for small-scale cell culture and fermentation applications. The Biostat B offers precise monitoring and control of key process parameters such as temperature, pH, and dissolved oxygen.
9
Glutamax by Thermo Fisher Scientific
Sourced in United States, Germany, United Kingdom, France, Switzerland, Canada, Japan, Australia, China, Belgium, Italy, Denmark, Spain, Austria, Netherlands, Sweden, Ireland, New Zealand, Israel, Gabon, India, Poland, Argentina, Macao, Finland, Hungary, Brazil, Slovenia, Sao Tome and Principe, Singapore, Holy See (Vatican City State)
GlutaMAX is a chemically defined, L-glutamine substitute for cell culture media. It is a stable source of L-glutamine that does not degrade over time like L-glutamine. GlutaMAX helps maintain consistent cell growth and performance in cell culture applications.
10
Biostat a by Sartorius
Sourced in Germany
The Biostat A is a compact and versatile bioreactor system from Sartorius. It is designed for small-scale cell culture and fermentation applications. The Biostat A provides precise control over key parameters such as temperature, pH, and dissolved oxygen levels to support optimal cell growth and product formation.

More about "Bioreactors"

Bioreactors are essential tools in the field of biotechnology, enabling the cultivation and production of a wide range of biological materials.
These specialized vessels provide a controlled environment for the growth and optimization of cells, tissues, and microbial cultures.
Researchers and industry professionals utilize bioreactors to manipulate key parameters such as temperature, pH, oxygen levels, and nutrient supply, with the aim of enhancing the yield, productivity, and quality of their desired products.
Bioreactors play a crucial role in a diverse array of applications, from pharmaceutical development to environmental biotechnology.
They contribute to advancements in fields like medicine, agriculture, and sustainable energy.
Ongoing research into bioreactor design, monitoring, and optimization continues to drive innovation and expand the capabilities of this versatile technology.
In addition to the core bioreactor, various supplementary components and reagents are often employed to support optimal cell growth and productivity.
These include serum (FBS), antibiotics (Penicillin/Streptomycin), antifoaming agents (Antifoam 204), and media supplements (L-glutamine, GlutaMAX).
Specialized bioreactor systems, such as the Biostat B Plus, Biostat A Plus, and BioFlo 110, offer advanced features and capabilities to meet the diverse needs of researchers and industry professionals.
The utilization of bioreactors, along with the careful selection and integration of supporting materials and equipment, is integral to the success of a wide range of biotechnological endeavors.
By leveraging this powerful technology, scientists and engineers can push the boundaries of what is possible in fields like medicine, agriculture, and sustainability.